articleTop 1% cited

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

Clinical Cancer Research · 2006 · Vol. 12(21) · pp. 6403–6409

G. Thomas Budd✉(Cleveland Clinic)Massimo Cristofanilli(The University of Texas MD Anderson Cancer Center)Mathew J. Ellis(Washington University in St. Louis)Allison Stopeck(University of Arizona)Ernest C. Borden(Cleveland Clinic)Michael Craig Miller(Eon Corporation (United States))Jeri Matera(Eon Corporation (United States))Madeline Repollet(Eon Corporation (United States))Gerald V. Doyle(Eon Corporation (United States))Leon W.M.M. Terstappen(Eon Corporation (United States))Daniel F. Hayes(Michigan Center for Translational Pathology)

View via DOI Publisher page

Abstract

Assessment of CTCs is an earlier, more reproducible indication of disease status than current imaging methods. CTCs may be a superior surrogate end point, as they are highly reproducible and correlate better with overall survival than do changes determined by traditional radiology.

Cancer Cells and Metastasis Lung Cancer Diagnosis and Treatment Cancer Genomics and DiagnosticsMedicineCirculating tumor cellMetastatic breast cancerBreast cancerOverall survivalCancerRadiologyOncologyMetastasisInternal medicine

MeSH terms

Breast NeoplasmsDouble-Blind MethodFemaleHumansMiddle AgedNeoplastic Cells, CirculatingPrognosisRadiographySensitivity and SpecificityReproducibility of ResultsObserver VariationSurvival AnalysisTreatment Outcome

Citations

787

FWCI

15.94

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer